Like eculizumab, nomacopan prevents cleavage and activation of C5 but it binds C5 at a different site, and this makes it a potentially useful agent to treat PNH patients who are resistant to eculizumab therapy because of C5 genetic variants [107]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.